Bethanechol

Bethanechol is a synthetic choline ester, classified as a direct-acting parasympathomimetic and a muscarinic acetylcholine receptor agonist ^[1]. Structurally it is a carbamate related to acetylcholine and methacholine, but two features set it apart: it selectively activates muscarinic receptors with essentially no action at nicotinic receptors, and it resists hydrolysis by cholinesterase enzymes. Because it is not quickly broken down, its cholinergic effect is far more sustained than that of acetylcholine itself.

The drug is used mainly to encourage emptying of a bladder that is not contracting adequately. Typical indications include urinary retention following surgery or childbirth, and retention associated with a neurogenic bladder, provided there is no physical blockage of urine outflow ^[1]. It has also been used for gastrointestinal atony, in which the stomach or bowel loses its normal muscular tone, and it has been studied as a stimulant of saliva production in people with dry mouth ^[4]. In everyday practice it is prescribed most often by urologists, chiefly to older adults with reduced bladder contractility such as detrusor atony or incomplete emptying ^[1].

The evidence supporting bethanechol is limited, and its role has narrowed over time. Reviews of underactive bladder have noted that, although the drug can in principle increase the strength of bladder muscle contraction, its measurable benefit in helping the bladder empty is small ^[2]. Analyses of geriatric bladder dysfunction have similarly concluded that bethanechol does not reliably improve bladder emptying ^[3]. In a study of radiation-related dry mouth it produced only a modest rise in resting saliva and worked no better than the alternative drug pilocarpine ^[4]. As a result, prescribing has declined, though it continues to be used in selected patients ^[1].

Because it broadly switches on the parasympathetic nervous system, bethanechol can affect many organs at once, which is why it is avoided in several conditions. It is contraindicated in people with asthma, peptic ulcer disease, coronary insufficiency, mechanical obstruction of the bladder or bowel, and overactive thyroid, since heightened cholinergic activity could worsen these problems ^[1]. In a hospital setting it has historically been paired with the anticholinergic drug atropine, which is given before an operation to quiet the bladder and bowel, after which bethanechol can be used to restore their activity.

Bethanechol is taken by mouth as tablets and can also be given by subcutaneous injection; it is not given intravenously or intramuscularly because of the risk of severe cholinergic reactions. It is marketed under names including Urecholine, Duvoid, and Urocarb, and is a prescription-only medicine, available as an inexpensive generic in many countries.

Bethanechol is prescription only. Because it amplifies cholinergic activity, side effects reflect that: sweating, excess saliva, flushing, watery eyes, abdominal cramps, nausea, diarrhea, and an urgent need to urinate. It can slow the heart and lower blood pressure and may tighten the airways. For that reason it is contraindicated in asthma and COPD, peptic ulcer disease, mechanical bladder or bowel obstruction, overactive thyroid, slow heart rate, coronary artery disease, epilepsy, and Parkinsonism, and it should never be given when there is a physical blockage. It is taken on an empty stomach to limit nausea and vomiting. Atropine is the antidote for severe reactions. Combining it with other cholinergic drugs deepens these effects.

Bethanechol is a direct muscarinic agonist that resists cholinesterase, so anything else pushing cholinergic tone adds to it without a brake.

Cholinesterase inhibitors are the clearest hazard. Neostigmine, pyridostigmine, donepezil and rivastigmine all raise synaptic acetylcholine, and combining them with bethanechol can produce a cholinergic excess of bradycardia, bronchospasm, cramping, sweating and involuntary voiding. Ganglionic blocking agents such as mecamylamine and trimethaphan are the classic labeled warning: with bethanechol they have caused severe hypotension, and case reports describe bradyarrhythmia progressing to asystole.

Beta blockers matter in the airway. Bethanechol constricts bronchial smooth muscle, and removing beta-2 mediated relaxation makes that worse, which is why the pairing is a concern in asthma.

In the opposite direction, antimuscarinics such as atropine, scopolamine, oxybutynin and tricyclic antidepressants block the receptor bethanechol is trying to stimulate and cancel its effect. Quinidine and procainamide similarly oppose cholinergic action on the heart.

Checking a whole stack? Run it through interactions + stacks.

Bethanechol is a synthetic choline ester introduced in the mid-twentieth century as a longer-acting relative of acetylcholine; structurally it is the beta-methyl, carbamate analog that combines features of methacholine and carbachol. The beta-methyl group and the carbamate linkage together make the molecule resistant to acetylcholinesterase and largely selective for muscarinic over nicotinic receptors, which was the design goal of producing a sustained, glandular and smooth-muscle stimulant. It became established under the brand name Urecholine for non-obstructive urinary retention and, less commonly, for gastrointestinal atony. It remains available as a generic prescription medicine.

Bethanechol occupies a well-defined niche as one of the few pharmacologic options for a poorly contracting bladder, and it continues to be prescribed, chiefly by urologists, for detrusor underactivity and incomplete emptying. Its reputation is that of a targeted, predictable cholinergic agent rather than a blockbuster; clinicians appreciate having a direct muscarinic stimulant available even while acknowledging that its real-world effect on bladder emptying is often modest. Its long clinical presence speaks to a favorable, well-characterized safety and mechanism profile when used thoughtfully. It endures because the therapeutic gap it addresses has few alternatives.